Quince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $4.00 price target on the stock.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Oppenheimer initiated coverage on Quince Therapeutics in a research report on Monday, March 24th. They issued an "outperform" rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Quince Therapeutics currently has an average rating of "Buy" and an average target price of $8.00.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX traded down $0.05 during trading on Friday, reaching $1.38. The stock had a trading volume of 210,039 shares, compared to its average volume of 296,727. The firm's 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.42. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The stock has a market cap of $62.75 million, a PE ratio of -1.11 and a beta of 0.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). On average, research analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

Institutional investors have recently bought and sold shares of the stock. Ieq Capital LLC acquired a new position in Quince Therapeutics during the 1st quarter valued at about $1,073,000. Shay Capital LLC raised its holdings in Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after purchasing an additional 104,616 shares in the last quarter. Intellectus Partners LLC acquired a new stake in Quince Therapeutics in the first quarter worth approximately $71,000. Geode Capital Management LLC increased its position in shares of Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock valued at $703,000 after purchasing an additional 36,807 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Quince Therapeutics in the 4th quarter worth $57,000. Institutional investors and hedge funds own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.